T Cell Non-Hodgkin Lymphoma - lenalidomide - TET2 mutation

Association details:

Biomarker:	TET2 mutation
Cancer:	T Cell Non-Hodgkin Lymphoma
Drug:	lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

Blood Adv

Title:

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

Published date:

01/22/2021

Excerpt:

Here, we present the results of a phase 2 trial combining lenalidomide and CHOP in previously untreated AITL patients aged 60 to 80 years...patients with mutations in the 3 epigenetic modifiers TET2, DNMT3A, and IDH2 had a poor prognosis, with a median OS of 14 months when treated with CHOP-based therapy.

Secondary therapy:

CHOP

DOI:

10.1182/bloodadvances.2020003081

Trial ID:

NCT01553786